2020年09月27日讯 /生物谷BIOON/ --礼来（Eli Lilly）近日宣布，加拿大卫生部（Health Canada）已批准降糖药Trulicity（dulaglutide，度拉鲁 ...

礼来（Eli Lilly）近日宣布，加拿大卫生部（Health Canada）已批准降糖药Trulicity（dulaglutide，度拉鲁肽），该药是一种每周一次的胰高血糖素样肽-1受体激动剂（GLP-1RA），适用于作为饮食、锻炼和标准护理疗法的辅助疗法，用于患有心血管（CV）疾病或存在多种 ...

2020年02月22日讯 /生物谷BIOON/ --礼来（Eli Lilly）近日宣布，美国食品和药物管理局（FDA）已批准每周一次胰高血糖素样肽-1受体 ...

The approval was based on data from the randomized, double-blind, parallel-arm phase 3 AWARD-11 trial. The Food and Drug Administration (FDA) has approved 2 additional dosage strengths of Trulicity ® ...

AWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint, both doses also led to weight loss INDIANAPOLIS, Sept. 3, 2020 /PRNewswire/ -- The U.S. Food and ...

- Trulicity, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for adults with type 2 diabetes as an adjunct to diet and exercise INDIANAPOLIS, Sept. 18, 2014 /PRNewswire/ -- ...

Eli Lilly and Company (LLY) announced that the FDA granted approval to two higher doses, 3 mg and 4.5 mg, of its GLP-1 receptor agonist, Trulicity. The approval was based on data from the AWARD-11 ...

Novo Nordisk’s Ozempic, grappling with Eli Lilly’s Trulicity for supremacy of the GLP-1 diabetes market, hit a snag last year when the FDA refused to review a new dosing regimen over the need for more ...

Trulicity is a prescription drug prescribed to lower blood glucose levels and treat type diabetes. Although it is FDA approved for treating diabetes it is not approved for weight loss. Despite this ...

New phase 3b trial results show Lilly’s Trulicity has helped type 2 diabetes patients already taking an SGLT2 inhibitor but whose blood sugar was inadequately controlled. The AWARD trial showed that ...

People with diabetes who take injectable medications like Trulicity and Ozempic have been scrambling to find their next dose. Erie-area pharmacies, like others across the country, can't get enough of ...

Gavreto approved for metastatic lung cancer with RET gene fusions Blueprint Medicines’ Gavreto (pralsetinib capsules) has been granted accelerated approval for treating adults with metastatic ...